Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial

Table 1 Literature review of hypofractionated radiotherapy schemes for the treatment of prostate cancer in the postoperative setting

Study (ref.)	Design	Setting (patient number)	Total dose, Gy	Dose per fraction, Gy	EQD2 (prostate cancer^a)	BED (early toxicity^a)	BED (late toxicity^a)
Tandberg [30]	Retrospective	Salv. (138)/Adj. (29)	65^b	2.5	74.29	81.25	119.17
Kruser [33]	Retrospective	Salv. (108)	65	2.5	74.29	81.25	119.17
Lewis [31]	Retrospective	Salv. (43)/Adj. (13)	65^b	2.5	71.43	78.13	114.58
Cuccia [32]	Retrospective	Salv. (38)/Adj. (37)	63.8	2.2	67.45	77.84	110.59
Barra [34]	Retrospective	Salv. (32)/Adj. (32)	62.5	2.5	71.43	78.13	114.58
Alongi [35]	Retrospective	Salv. (9)/Adj. (30)	70^b	2.5	80	87.5	128.33
Saldi [27]	Phase I/II	Salv. (72)/Adj. (40)	72–74.25^c	2.25	77.14–79.55	88.2–90.96	126–129.94
Katayama [26]	Phase I/II	Salv. (28)/Adj. (11)	54	3	69.43	70.2	108
Gladwish [29]	Phase I/II	Salv. (26)/Adj. (4)	51	3	65.57	66.3	102
Macchia [28]	Phase I/II	Salv. (18)/Adj. (106)	62.5	2.5	71.43	78.13	114.58
This study	Phase III	Salv. (288)	65	2.5	74.29	81.25	119.17

EQD2 equivalent dose in 2-Gy fractions, BED biologically equivalent dose, Salv. salvage, Adj. adjuvant
^aα/β ratio for prostate cancer is 1.5, 10 for early-responding normal tissue, and 3 for late-responding normal tissue
^bMedian
^cSalvage

ISSN: 1745-6215